GLUT4 translocation is not impaired after acute exercise in skeletal muscle of women with obesity and polycystic ovary syndrome.

OBJECTIVE: The aim of this study was to examine the effects of acute exercise on insulin signaling in skeletal muscle of women with polycystic ovary syndrome (PCOS) and controls (CTRL). METHODS: Fifteen women with obesity and PCOS and 12 body mass index-matched CTRL participated in this study. Subjects performed a 40-min single bout of exercise. Muscle biopsies were performed before and 60 min after exercise. Selected proteins were assessed by Western blotting. RESULTS: CTRL, but not PCOS, showed a significant increase in PI3-k p85 and AS160 Thr 642 after a single bout of exercise (P = 0.018 and P = 0.018, respectively). Only PCOS showed an increase in Akt Thr 308 and AMPK phosphorylation after exercise (P = 0.018 and P = 0.018, respectively). Total GLUT4 expression was comparable between groups (P > 0.05). GLUT4 translocation tended to be significantly higher in both groups after exercise (PCOS: P = 0.093; CTRL: P = 0.091), with no significant difference between them (P > 0.05). CONCLUSIONS: A single bout of exercise elicited similar GLUT4 translocation in skeletal muscle of PCOS and CTRL, despite a slightly differential pattern of protein phosphorylation. The absence of impairment in GLUT4 translocation suggests that PCOS patients with obesity and insulin resistance may benefit from exercise training.

Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without major cardiovascular risk factors.

OBJECTIVE: The aim of this study was to evaluate the influence of polycystic ovary syndrome (PCOS) and obesity on circulating markers of low-grade inflammation-tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6) and high sensitive C-reactive protein (hsCRP)-in young women without major cardiovascular (CV) risk factors (diabetes, dyslipidemia and arterial hypertension). DESIGN: Twenty-five young women with PCOS and 23 eumenorrheic women without major CV risk factors and matched for body mass index (BMI) were studied. They were subdivided according to BMI and PCOS status and comparisons were made between the PCOS and Control groups, regardless of BMI, and between the Obese and Lean groups, regardless of the presence of PCOS. RESULTS: Levels of TNF-α, IL-6 and hsCRP were similar between the PCOS group and the Control group (2.1 vs 1.9 pg/ml, p=0.397, 3.8 vs 5.7 pg/ml, p=0.805 and 0.9 vs 0.5 ng/ml, p=0.361, respectively). Levels of TNF-α were similar between the obese group and the lean group (2.1 vs 1.9 pg/ml, p=0.444). Levels of IL-6 and hsCRP were higher in the obese group than in the lean group (8.7 vs 2.0, p <0.001 and 1.4 vs 0.2 ng/ml, p <0.001, respectively). CONCLUSION: Obesity, but not polycystic ovary syndrome, affects circulating markers of low-grade inflammation in young women without major CV risk factors.

Metabolic disturbance in PCOS: clinical and molecular effects on skeletal muscle tissue.

Polycystic ovary syndrome is a complex hormonal disorder affecting the reproductive and metabolic systems with signs and symptoms related to anovulation, infertility, menstrual irregularity and hirsutism. Skeletal muscle plays a vital role in the peripheral glucose uptake. Since PCOS is associated with defects in the activation and pancreatic dysfunction of ß-cell insulin, it is important to understand the molecular mechanisms of insulin resistance in PCOS. Studies of muscle tissue in patients with PCOS reveal defects in insulin signaling. Muscle biopsies performed during euglycemic hyperinsulinemic clamp showed a significant reduction in glucose uptake, and insulin-mediated IRS-2 increased significantly in skeletal muscle. It is recognized that the etiology of insulin resistance in PCOS is likely to be as complicated as in type 2 diabetes and it has an important role in metabolic and reproductive phenotypes of this syndrome. Thus, further evidence regarding the effect of nonpharmacological approaches (e.g., physical exercise) in skeletal muscle of women with PCOS is required for a better therapeutic approach in the management of various metabolic and reproductive problems caused by this syndrome.

Polycystic ovary syndrome and obesity do not affect vascular parameters related to early atherosclerosis in young women without glucose metabolism disturbances, arterial hypertension and severe abnormalities of lipid profile.

The aim of this study was to evaluate the influence of polycystic ovary syndrome (PCOS) and obesity on vascular parameters related to early atherosclerosis (VP-EA) [brachial flow-mediated dilation (FMD), carotid intima-media thickness (CIMT) and carotid arterial compliance (CAC)] in women with minor cardiovascular risk factors (CVRFs). Twenty-five young women with PCOS and 23 eumenorrheic women matched for body mass index (BMI) were studied. The women were subdivided according to BMI and PCOS status, and comparisons were done between PCOS and Control group, regardless of BMI, and between Obese and Lean group, regardless of the presence of PCOS. Insulin resistance was higher in PCOS-group than in control-group and in obese-group than in lean-group. The median of all VP-EA evaluated were similar between PCOS-group and Control-group [FMD: 6.6 versus 8.4% (p = NS); CIMT: 48.0 versus 47.0 mm.10-2 (p = NS); CAC: 6.2 versus 5.6N-1.m4.10-10 (p = NS)] and between obese-group and lean-group [FMD: 7.8 versus 6.6% (p = NS); CIMT: 48.0 versus 47.0 mm.10-2 (p = NS); CAC: 5.7 versus 6.3N-1.m4.10-10 (p = NS)]. These results suggest that PCOS and obesity do not affect VP-EA in women with minor CVRFs.

Testosterona falsamente elevada em uma paciente diabética tipo 1 com acne e insuficiência renal crônica em diálise / Falsely elevated testosterone in a type 1 diabetes patients with acne and chronic renal failure on dyalisis

Descrevemos uma paciente com diabetes tipo 1 com acne e insuficiência renal crônica, em diálise, que apresentou uma dosagem de testosterona total e livre elevada (612 ng/dL, normal < 90 ng/dL e 255 pMol/L, normal: 20-45 pMol/L, respectivamente). Na avaliação clínica, além da acne facial não havia qualquer outro sinal de hiperandrogenismo. Após ter esse resultado confirmado, ela foi submetida à avaliação morfológica de adrenal e ovários (tomografia computadorizada de adrenal e ultrassom pélvico), cujos resultados foram normais. Na ausência de quadro clínico de virilização, foram consideradas outras possibilidades que pudessem explicar a elevação da testosterona, entre as quais a presença de comorbidades (diabetes e insuficiência renal crônica) e falha do método de dosagem. Uma nova determinação da testosterona total, por meio da cromatografia líquida de alta performance como método preparativo e espectrometria de massa em tandem, resultou normal (21 ng/dL), compatível com uma concentração de testosterona total falsamente elevada pela presença de interferentes com o método de dosagem.

The purpose of this report is to present the case of a patient with type 1 diabetes with acne and chronic renal failure on dialysis admitted to the hospital with high total total and free testosterone (612 ng/dL, normal < 90 ng/dL; 255 pMol/L, normal: 20-45 pMol/L). On clinical evalua­tion, she presented facial acne, and no other signs of hyperandrogenism. As this result was confirmed, she underwent adrenal and ovary morphological assessment (adrenal CT and pelvic ultrasound), which yielded normal results. Due to divergence between clinical and laboratory findings, we considered other possibilities that could explain the elevation of testosterone, including the presence of comorbidities (diabetes and chronic renal failure) and failure of the testosterone assay. Testosterone levels were determined again by high performance liquid chromatography, as a preparative method, and tandem mass spectrometry, yielding normal results (21 ng/dL), which were compatible with a falsely elevated total testosterone level caused by the presence of factors that intereferred with the assay.

Metformin versus lifestyle changes in treating women with polycystic ovary syndrome.

OBJECTIVE: To compare the efficacy of metformin with that of lifestyle changes in patients with polycystic ovary syndrome (PCOS). DESIGN: Prospective, randomized clinical trial of 40 women with PCOS to analyze the effects of metformin and lifestyle intervention treatments on menstrual pattern and hormone and metabolic profile. The duration of treatment was 6 months. Statistical analysis was done using Student's t-test. RESULTS: Fifteen women in the metformin group and 12 in the lifestyle changes group completed the study. The menstrual pattern improved by ~67% in both groups. There was a significant decrease in waist circumference in the lifestyle changes group (101.8 ± 3.9 and 95.1 ± 3.6, at baseline and at 6 months of treatment, respectively; p < 0.001) and in body mass index (BMI) in both groups. The predictor of menstrual pattern improvement was BMI. CONCLUSIONS: Both metformin and lifestyle changes may increase the number of menstrual cycles in PCOS. This effect was related to a decrease in BMI.

Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome.

OBJECTIVE: To search for predictors of metformin response in women with polycystic ovary syndrome (PCOS) through a detailed analysis of clinical and laboratory parameters. STUDY DESIGN: We designed a prospective study to investigate clinical and laboratory parameters to search for predictors of metformin response in women with PCOS. A total of 53 PCOS patients were given metformin 850 mg twice a day for 6 months, after which patients were classified as responders or non-responders. Parameters analyzed for comparison between the two groups were: plasma fasting insulin glucose/insulin ratio; oral glucose tolerance test (OGTT) with insulin (120 min); HOMA and QUICKI tests; total cholesterol and fractions, triglycerides; LH, FSH, estradiol, progesterone, testosterone, androstenedione, 17-OH progesterone, and DHEAS. RESULTS: From all patients, 30 (56.6%) were responders and 23 (43.3%) were non-responders. Multinomial analysis showed that the positive response to metformin was associated with higher levels of basal LH (p=0.038) and lower levels of high-density lipoprotein cholesterol (HDL-C) (p=0.015). CONCLUSION: In weight-matched PCOS subjects, laboratory markers might predict the metformin response. Higher levels of basal LH and lower levels of HDL-C are correlated with a positive response to metformin treatment in PCOS subjects.

[Difficulties and pitfalls in the diagnosis of polycystic ovary syndrome]. / Dificuldades e armadilhas no diagnóstico da síndrome dos ovários policísticos.

The polycystic ovary syndrome is one of the most common endocrinopathies, affecting approximately 7% of women of reproductive age. Although it was described in 1935, only in 1990 was published the first Consensus regarding it its diagnosis. Today, the syndrome is also considered a cardiovascular risk factor, with a high prevalence of metabolic disorders. Reflecting this new vision of the syndrome, several documents, including Consensus, Statement and Guidelines have been published, addressing different aspects of the syndrome. This review is an analysis of documents obtained through a survey in the PubMed database, using the keywords "polycystic ovary syndrome", "hyperandrogenism" and "hirsutism", separately, taking as limiting the term Type of Article (Practice Guideline, Consensus Development Conference, Guideline) without limitation of time, language and age, having been selected only those documents prepared under the sponsorship of Medical Entities and with more than one author.

Dificuldades e armadilhas no diagnóstico da síndrome dos ovários policísticos / Difficulties and pitfalls in the diagnosis of polycystic ovary syndrome

A síndrome dos ovários policísticos é uma das endocrinopatias mais comuns, afetando aproximadamente 7 por cento das mulheres na idade reprodutiva. Embora tenha sido descrita em 1935, somente em 1990 foi elaborado o primeiro consenso com relação ao seu diagnóstico. Hoje, a síndrome é considerada também um fator de risco cardiovascular, com uma alta prevalência de distúrbios metabólicos. Como reflexo dessa nova visão da síndrome, vários documentos, entre Consensos, Posicionamentos e Orientações, têm sido publicados, abordando diversos aspectos da síndrome. O objetivo desta revisão é uma análise crítica desses documentos, obtidos mediante um levantamento na base PubMed, por meio dos unitermos polycystic ovary syndrome, hyperandrogenism e hirsutism, separadamente, tendo como limitador o termo Type of Article (Practice Guideline, Consensus Development Conference, Guideline), sem limitação de data, língua e idade. Foram selecionados apenas os documentos elaborados sob patrocínio de Entidades Médicas e com mais de um autor.

The polycystic ovary syndrome is one of the most common endocrinopathies, affecting approximately 7 percent of women of reproductive age. Although it was described in 1935, only in 1990 was published the first Consensus regarding it its diagnosis. Today, the syndrome is also considered a cardiovascular risk factor, with a high prevalence of metabolic disorders. Reflecting this new vision of the syndrome, several documents, including Consensus, Statement and Guidelines have been published, addressing different aspects of the syndrome. This review is an analysis of documents obtained through a survey in the PubMed database, using the keywords "polycystic ovary syndrome", "hyperandrogenism" and "hirsutism", separately, taking as limiting the term Type of Article (Practice Guideline, Consensus Development Conference, Guideline) without limitation of time, language and age, having been selected only those documents prepared under the sponsorship of Medical Entities and with more than one author.

Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors.

The aim of this study was to determine the prevalence of metabolic syndrome in women with polycystic ovary syndrome, as well as its characteristics and predictors. Seventh-three women, with body mass index of 30.4 +/- 7.8 kg/m2 and 25.0 +/- 6.0 years old, subdivided according to body mass index, were studied retrospectively. There was no significant mean age difference among body mass index groups (p = 0.228). Prevalence of metabolic syndrome was 38.4%, with a null prevalence for normal (n = 18), 23.8% for overweight (n = 17), 62.9% for obese (n = 28), and 85.5% for morbidly obese women (n = 7). Women with metabolic syndrome were older than women without metabolic syndrome (27.3 +/- 5.3 vs. 24.2 +/- 4.6 vs. years old; p = 0.031) and presented a higher body mass index (36.3 +/- 7.7 vs. 26.9 +/- 5.4; p < 0.001). There was no difference for degree of hirsutism and menstrual patterns between women with and without metabolic syndrome (p = 0.593 and p = 0.119, respectively). Regarding laboratory parameters, DHEAS was lower (1,646 +/- 1,007 vs. 2,594 +/- 1,563; p = 0.007) and HOMA-IR were higher (9.9 +/- 9.7 vs. 4.6 +/- 4.7; p = 0.004) in women with metabolic syndrome (p = 0.031 and p < 0.001, respectively). The best predictors of metabolic syndrome were waist circumference > 88 cm, HDL-cholesterol < 50 mg/dL and triglycerides >or= 150 mg/dL.

Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors

The aim of this study was to determine the prevalence of metabolic syndrome in women with polycystic ovary syndrome, as well as its characteristics and predictors. Seventh-three women, with body mass index of 30.4 ± 7.8 kg/m² and 25.0 ± 6.0 years old, subdivided according to body mass index, were studied retrospectively. There was no significant mean age difference among body mass index groups (p = 0.228). Prevalence of metabolic syndrome was 38.4 percent, with a null prevalence for normal (n = 18), 23.8 percent for overweight (n = 17), 62.9 percent for obese (n = 28), and 85.5 percent for morbidly obese women (n = 7). Women with metabolic syndrome were older than women without metabolic syndrome (27.3 ± 5.3 vs. 24.2 ± 4.6 vs. years old; p = 0.031) and presented a higher body mass index (36.3 ± 7.7 vs. 26.9 ± 5.4; p < 0.001). There was no difference for degree of hirsutism and menstrual patterns between women with and without metabolic syndrome (p = 0.593 and p = 0.119, respectively). Regarding laboratory parameters, DHEAS was lower (1,646 ± 1,007 vs. 2,594 ± 1,563; p = 0.007) and HOMA-IR were higher (9.9 ± 9.7 vs. 4.6 ± 4.7; p = 0.004) in women with metabolic syndrome (p = 0.031 and p < 0.001, respectively). The best predictors of metabolic syndrome were waist circumference > 88 cm, HDL-cholesterol < 50 mg/dL and triglycerides > 150 mg/dL.

O objetivo deste estudo foi o de determinar a prevalência, características e preditores da síndrome metabólica em mulheres com a síndrome dos ovários policísticos. Setenta e três mulheres, com índice de massa corporal de 30,4 ± 7,8 kg/m² e 25,0 ± 6,0 anos de idade, subdivididas de acordo com o índice de massa corporal, foram estudadas retrospectivamente. Não se observou diferença significativa de idade entre os grupos (p = 0,228). A prevalência da síndrome metabólica foi de 38,4 por cento, estando ausente nas mulheres com índice de massa corporal normal (n = 18) e presente em 23,8 por cento das com sobrepeso (n = 17), 62,9 por cento das obesas (n = 28) e 85,5 por cento das obesas mórbidas (n = 7). Quando comparadas, as mulheres com síndrome metabólica apresentaram uma idade mais avançada (27,3 ± 5,3 vs. 24,2 ± 4,6 anos; p = 0,031) e um índice de massa corporal maior (36,3 ± 7,7 vs. 26,9 ± 5,4; p < 0,001) que as mulheres sem a síndrome, não havendo diferença significativa com relação ao grau de hirsutismo (p = 0,593) e padrão menstrual (p = 0,119). Com relação aos parâmetros laboratoriais, a concentração de DHEAS foi menor (1.646 ± 1.007 vs. 2.594 ± 1.563; p = 0,007) e o valor do HOMA-IR foi maior (9,9 ± 9,7 vs. 4,6 ± 4,7; p = 0,004) nas pacientes com a síndrome metabólica. Os melhores preditores para a presença da síndrome metabólica foram a circunferência abdominal > 88 cm, HDL-colesterol < 50 mg/dL e triglicérides > 150 mg/dL.

Hirsutismo: diagnóstico diferencial / Hirsutism: differential diagnosis

O hirsutismo é um dos sinais das síndromes hiperandrogênicas. Uma abordagem prática consiste em dividir as síndromes hiperandrogênicas em virilizantes e não virilizantes, de acordo com a presença ou ausência de sinais de virilização. Um caso de uma paciente com hirsutismo e com uma concentração basal e após estímulo com ACTH(1-24) elevada de 17-OHP é discutido. A ausência de sinais de virilização e a história clínica tornavam pouco prováveis etiologias como neoplasias virilizantes e a hipertecose de ovário. Dentre as causas das síndromes não virilizantes, a presença de distúrbio menstrual e hiperandrogenemia descartou o hirsutismo idiopático. De acordo com o Consenso de Rotterdam, considerou-se o diagnóstico de síndrome dos ovários policísticos, procedendo-se à exclusão da forma não clássica da hiperplasia adrenal congênita por deficiência da 21-hidroxilase. A concentração de 17-OHP após estímulo foi de 14 ng/dL, sendo que, na dependência do limite de corte considerado, seria compatível com esta doença. Embora a região promotora do gene não tenha sido estudada, do ponto de vistas prático pode-se considerar que este diagnóstico tenha sido excluído, uma vez que mutações nessa região são raras.

Hirsutism is one of the manifestations of the hyperandrogenic syndromes. A practical approach consists of dividing the hyperandrogenic syndromes into virilizing and non-virilizing, in accordance to the presence or absence of virilization symptoms. A case of a patient with hirsutism and a high basal and post-ACTH stimulation concentration of 17-OHP is presented. The absence of virilization and of clinical history discarded as etiology the virilizing neoplasias and hiperthecose of the ovary. Among the causes of non-virilizing syndromes, the presence of the menstrual disturbance and hiperandrogenemia discarded idiopathic hirsutism. In accordance to the Consensus of Rotterdam, the diagnosis of polycystic ovary syndrome was considered. For to exclude the non classic form of congenital adrenal hyperplasia due to 21-hidroxilase deficiency, the patient was submitted to a short ACTH-(1-24) stimulation test. The 17-OHP concentrations after stimuli were 14 ng/dL, being that, in the dependence of the limit of considered cut-off, it would be compatible with this illness. Although the promoter region had not been studied, we can consider that this diagnosis was excluded through the sequencing of CYP21A2 gene, since mutation on the promoter region is a rare event.

[Hirsutism: differential diagnosis]. / Hirsutismo: diagnóstico diferencial.

Hirsutism is one of the manifestations of the hyperandrogenic syndromes. A practical approach consists of dividing the hyperandrogenic syndromes into virilizing and non-virilizing, in accordance to the presence or absence of virilization symptoms. A case of a patient with hirsutism and a high basal and post-ACTH stimulation concentration of 17-OHP is presented. The absence of virilization and of clinical history discarded as etiology the virilizing neoplasias and hyperthecose of the ovary. Among the causes of non-virilizing syndromes, the presence of the menstrual disturbance and hyperandrogenemia discarded idiopathic hirsutism. In accordance to the Consensus of Rotterdam, the diagnosis of polycystic ovary syndrome was considered. For to exclude the non classic form of congenital adrenal hyperplasia due to 21-hydroxylase deficiency, the patient was submitted to a short ACTH-(1-24) stimulation test. The 17-OHP concentrations after stimuli were 14 ng/dL, being that, in the dependence of the limit of considered cut-off, it would be compatible with this illness. Although the promoter region had not been studied, we can consider that this diagnosis was excluded through the sequencing of CYP21A2 gene, since mutation on the promoter region is a rare event.

Comparação entre diferentes índices de avaliação da sensibilidade à insulina na síndrome dos ovários policísticos / Comparison among different insulin sensitivity indices in polycystic syndrome

Objetivo: Comparar os diferentes índices de avaliação da sensibilidade à insulina em mulheres portadoras da síndrome dos ovários policísticos (SOP), correlacionando-se com o índice de massa corpórea (IMC); avaliar o valor preditivo de IMC, insulina e glicemia de jejum na detecção da sensibilidade à insulina. Método: Foram estudadas 62 pacientes com idades variandio de 16 a 39 anos (média 25)portadoras da SOP diagnosticadas segundo Consenso 1990 (NHI). Vinte e cinco...

Avaliação da utilidade do estímulo agudo das gonadotrofinas e dos esteróides ovarianos com análogo do hormônio liberador de gonadotrofinas no diagnóstico diferencial do hiperandrogenismo ovariano funcional / Assessment of the utility of gonadotropins and ovarian steroids response to acute simulation with gonadotropin-releasing hormone analogue (GnRHa) in the differential diagnosis of functional ovarian hyperandrogenism

A resposta da 17-hidroxiprogesterona (170HP) ao estímulo agudo com um análogo do hormônio liberador de gonadotrofinas (GnRHa) e sua relação com a sensibilidade à insulina (SI) foi avaliada em 8 mulheres voluntárias normais e obesas (grupo N), com idades entre 24 e 40 anos (mediana de 29) e índice de massa corpóreo (IMC) entre 32,0 e 46,5kg/m2 (mediana de 35,7) e 8 pacientes portadoras da síndrome dos ovários policísticos (grupo SOP) com idades entre 19 e 28 anos (mediana de 26) e IMC entre 30,1 e 40,lkg/m2 (mediana de 35,8), submetidas a estímulo agudo com acetato de leuprolide, l ONg/kg SC e a teste de tolerância oral à glicose (TTOG). Observou-se aumento significativo da concentração de 170HP, tanto no grupo N (1,5 vs. 2,9ng/mL; p= 0,023) quanto no grupo SOP (0,8 vs. 3,lng/mL; p= 0,007), não havendo diferença significativa entre os grupos. A SI foi avaliada através da área sob a curva de insulina (ASCI) no TTOG. O grupo N apresentou ASCI significativamente menor que o grupo SOP (14.384 vs. 22.800uU1/mL/min, p= 0,04). Não houve correlação entre a concentração de 170HP após estímulo e a ASCI.

Diabetes e transplante de pâncreas / Diabetes and pancreas transplant

Os autores fazem uma revisão sobre transplante de pâncreas em pacientes diabéticos